by The global Acellular Dermal Matrices Market is estimated to be valued at US$ 8.8 Bn or Mn in 2023 and is expected to exhibit a CAGR of 12.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Acellular dermal matrices (ADMs) are thin sheets processed from human or animal (cadaveric) skin and used as surgical grafts. The decellularization process removes cellular antigens while preserving key structural proteins that facilitate cellular repopulation and tissue remodeling. ADMs offer several advantages over autologous skin grafts including reduced donor site morbidity, lower risk of rejection, and availability in various shapes and sizes. They are commonly used in reconstructive procedures like breast reconstruction following mastectomy and treatment of cutaneous defects caused by skin cancer, trauma, or burns.
Market Key Trends:
One of the key trends in the acellular dermal matrices market is rising adoption in breast reconstruction procedures. ADMs are increasingly preferred over implants alone or tissue expanders as they provide better cosmetic outcomes and higher satisfaction rates for breast reconstruction patients. The use of ADMs reduces surgical time and allows for one-stage rather than multiple staged reconstruction processes. Additionally, technical innovations like engineered products combining ADM with fat or stem cells are further enhancing reconstruction outcomes, driving their uptake in breast surgery.
Porter’s Analysis
Threat of new entrants: Low. Existing players have established relations with healthcare providers and customers. Significant capital is required to conduct R&D for product development.
Bargaining power of buyers: High. Buyers have several options to choose from with various players offering acellular dermal matrices. Buyers can negotiate on price and quality.
Bargaining power of suppliers: Moderate. Suppliers of raw materials have some influence over pricing due to specialized manufacturing process. However, suppliers are fewer.
Threat of new substitutes: Low. There are limited substitutes which can match the efficiency of acellular dermal matrices for tissue repair.
Competitive rivalry: High. Major players compete on basis of product innovation, quality, and pricing. Intense competition to capture market share exists.
Key Takeaways
The global Acellular Dermal Matrices Market is expected to witness high growth, exhibiting a CAGR of 12.1% over the forecast period 2023-2030, due to increasing demand for advanced wound care products and reconstructive procedures. The market size was valued at US$ 8.8 Bn in 2023.
The US dominates the global market and is estimated to maintain its lead over the forecast period owing to the growing number of elderly population and cases of diabetes. Factors such as rising awareness about advanced wound care treatments and favorable reimbursement policies are fueling the market in the US.
Key players operating in the acellular dermal matrices market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
